Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures.

Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development Authority (BARDA). The newco has also raised $2.8 million in a series A round from a syndicate including Alexandria Venture Investments, Arch Venture Partners, Eli Lilly and Co. (NYSE:LLY), the J&J Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF and WuXi AppTec Corporate Ventures...